87 results
8-K
EX-1.1
STRO
Sutro Biopharma Inc
2 Apr 24
Entry into a Material Definitive Agreement
5:10pm
. The Company acknowledges and agrees that:
(a)each Underwriter’s responsibility to the Company is solely contractual in nature, the Representative have … responsibility to the Company is solely contractual in nature and the Underwriters do not owe the Company, or any other party, any fiduciary duty as a result
424B5
STRO
Sutro Biopharma Inc
2 Apr 24
Prospectus supplement for primary offering
4:58pm
have referred you. Neither we nor the underwriters take any responsibility for, nor do we provide any assurance as to the reliability of, any other … person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved
8-K
EX-99.1
STRO
Sutro Biopharma Inc
2 Apr 24
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
6:04am
responsibility for Phase I preparation activities, including submission of the Investigational New Drug (IND) application, and all subsequent clinical-development
8-K
EX-1.1
073h15er7e4u bhed7nd
9 Feb 24
Other Events
4:27pm
424B5
g3l4isttkcu1m
9 Feb 24
Prospectus supplement for primary offering
4:25pm
8-K
EX-99.1
gf3je
8 Jan 24
Results of Operations and Financial Condition
7:31am
8-K
EX-99.1
hd3ud
15 May 23
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
8:01am
PRE 14A
ma2o8swptphr0o937p
14 Apr 23
Preliminary proxy
4:05pm